VP, DM1 Commercial Asset Lead

The role

The VP, DM1 Commercial Asset Lead develops and implements commercialization strategies for the DM1 asset. This person leads global launch planning, market analysis, and competitive positioning within the neuromuscular portfolio.

What you will do

• Define global asset commercialization strategy and plan
• Shape competitive positioning and differentiation strategy
• Provide commercialization input into program strategy
• Establish strategic imperatives and execution priorities
• Lead global launch planning and readiness across key markets
• Partner with cross-functional teams to prepare for launch execution
• Collaborate with affiliate teams to support reimbursement and access readiness
• Serve as a key member of the Program Team and lead the DM1 Commercial Sub-Team
• Build a presence within the DM1 community including KOLs and patient advocacy groups
• Support preparation of commercialization materials for senior leadership and Board discussions

Required qualifications

• Bachelor’s degree in a relevant scientific, medical, or business discipline
• Minimum of 20 years of experience in the biopharmaceutical industry
• 15+ years of commercialization and cross-functional leadership experience
• Extensive experience leading global product launches, including a minimum of 3 launches
• Proven track record of delivering on business objectives in fast-paced, high-stakes environments
• Proven ability to steer assets from late-stage development through approval and launch
• Experience influencing global and U.S. market access and reimbursement readiness
• Demonstrated success developing global commercialization strategies
• Experience collaborating across clinical, medical, regulatory, supply, and commercial functions
• Ability to synthesize complex data to guide strategy
• Strong cross-functional leadership and stakeholder influence
• Proven ability to inspire and mobilize high-performing teams

Nice to have

• advanced degree
• Rare disease experience
• neuromuscular experience

About the company

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).